Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition

Methods Mol Biol. 2021:2262:311-321. doi: 10.1007/978-1-0716-1190-6_19.

Abstract

This chapter will describe how mathematical modeling allows the RAS pathway to be studied with computational experiments. The mathematical model utilized simulates the biochemical reactions that regulate RAS signaling. This type of model incorporates knowledge of reaction mechanisms, including measured quantitative parameters that characterize these reactions for both wild-type and mutant RAS proteins. For an illustrative example, this chapter focuses on how modeling provided new insights that helped solve a problem that challenged the RAS community for nearly a decade: why do colorectal cancers with the KRAS G13D mutation, but not the other common KRAS mutations, benefit from EGFR inhibition? The methods described include computational dose-response experiments and the use of "computational chimeric" RAS mutants.

Keywords: Computational biology; Systems biology; Systems pharmacology; Targeted therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Models, Theoretical*
  • Molecular Targeted Therapy / methods*
  • Mutation*
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins p21(ras) / genetics*

Substances

  • KRAS protein, human
  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins p21(ras)